vimarsana.com

Latest Breaking News On - விரிவான கிட்நீ பராமரிப்பு ஒப்பந்தம் - Page 1 : vimarsana.com

Fresenius Medical Care Q1 Results Down; Confirms FY21 Outlook

Fresenius Medical Care Q1 Results Down; Confirms FY21 Outlook Basic earnings per share decreased 10 percent to 0.85 euro from 0.95 euro a year ago. Operating income fell 15 percent to 474 million euros from last year s 555 million euros. Operating margin was 11.3 percent, down from 12.4 percent a year ago. Revenue declined 6 percent to 4.21 billion euros from prior year s 4.49 billion euros. Revenues grew 1 percent at constant currency. Organic growth amounted to 1 percent. Further, the company confirmed fiscal 2021 financial targets stating that the underlying development in the first three months was in line with expectations. The Company continues to expect revenue to grow at a low- to mid-single digit percentage rate and net income to decline at a high-teens to mid-twenties percentage rate against the 2020 base.

CMS Delays Start of First Performance Year Period for Kidney Care Choices Model | McGuireWoods LLP

To embed, copy and paste the code into your website or blog: On March 5, 2020, the Centers for Medicare & Medicaid Services (CMS) Innovation Center announced that it is delaying the inception of the Kidney Care Choices (KCC) Model’s first performance year until Jan. 1, 2022. The CMS’ KCC Model’s Kidney Care First (KCF) Option and the Comprehensive Kidney Care Contracting (CKCC) Option incentivize healthcare providers to manage the care of Medicare beneficiaries with chronic kidney disease stages 4 and 5 and end-stage renal disease. Unlike prior value-based kidney care models, the KCF and CKCC options are voluntary models that include both chronic kidney disease and end-stage renal disease beneficiaries, but align patients based on nephrology care, rather than based on dialysis treatments.

Why CMS Will Lead the 2021 Kidney Care Revolution -

by Chris Riopelle, CEO of Strive Health Chris Riopelle, CEO of Strive Health After an unprecedented year, kidney care providers, including nephrologists, dialysis facilities, and care extenders are expecting 2021 to follow suit. We will see an overhaul in reimbursement and major industry shifts, partly led by CMS, that will require providers to advance their capabilities in a way that will usher in more widespread innovation. These new models encourage a shift in treatment approach that will deliver earlier interventions and better outcomes.  The following are likely trends we will see in the new year.  Value-based Incentives Impact Kidney Care in 2021 

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.